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Toll-like receptor-4 regulation of hepatic Cyp3a11 metabolism in a mouse
model of LPS-induced CNS inflammation
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Goralski, Kerry B., Dalya Abdulla, Christopher J. Sinal, Andre
Arsenault, and Kenneth W. Renton. Toll-like receptor-4 regulation of
hepatic Cyp3a11 metabolism in a mouse model of LPS-induced CNS
inflammation. Am J Physiol Gastrointest Liver Physiol 289: G434–G443,
2005. First published May 5, 2005; doi:10.1152/ajpgi.00562.2004.—
Central nervous system (CNS) infection and inflammation severely
reduce the capacity of cytochrome P-450 metabolism in the liver. We
developed a mouse model to examine the effects of CNS inflamma-
tion on hepatic cytochrome P-450 metabolism. FVB, C57BL/6, and
C3H/HeouJ mice were given Escherichia coli LPS (2.5 g) by
intracerebroventricular (ICV) injection. The CNS inflammatory re-
sponse was confirmed by the elevation of TNF- and/or IL-1
proteins in the brain. In all mouse strains, LPS produced a 60–70%
loss in hepatic Cyp3a11 expression and activity compared with
saline-injected controls. Adrenalectomy did not prevent the loss in
Cyp3a11 expression or activity, thereby precluding the involvement
of the hypothalamic-adrenal-pituitary axis. Endotoxin was detectable
(1–10 ng/ml) in serum between 15 and 120 min after ICV dosing of
2.5 g LPS. Peripheral administration of 2.5 g LPS by intraperito-
neal injection produced similar serum endotoxin levels and a similar
loss (60%) in Cyp3a11 expression and activity in the liver. The loss
of Cyp3a11 in response to centrally or peripherally administered LPS
could not be evoked in Toll-like receptor-4 (TLR4)-mutant (C3H/
HeJ) mice, indicating that TLR4 signaling pathways are directly
involved in the enzyme loss. In summary, we conclude that LPS is
transferred from the brain to the circulation in significant quantities in
a model of CNS infection or inflammation. Subsequently, LPS that
has reached the circulation stimulates a TLR4-dependent mechanism
in the periphery, evoking a reduction in Cyp3a11 expression and
metabolism in the liver.
lipopolysaccharide; cytochrome P-450; drug metabolism
THE CYTOCHROMES P-450 are a gene superfamily of heme-
containing enzymes that contribute to the metabolism and
elimination of exogenous and endogenous substances (1, 5).
The highest amounts of drug-metabolizing cytochromes P-450
are found in the liver and intestine, with lower amounts found
in other organs, including the kidney, lung, and brain. In
rodents and humans, enzymes of the CYP3A subfamily com-
prise the majority of cytochrome P-450 in the liver (30–50%)
and metabolize 50–60% of clinically used drugs (1).
It is well known that cytochromes P-450 are modulated
during inflammatory responses and/or infectious diseases (28,
39). In general, acute systemic inflammatory responses trigger
reductions in hepatic cytochrome P-450 enzyme expression
and activity, with the consequence of reduced drug metabolism
during episodes of inflammation. Bacterial LPS is the major
stimulus for inflammatory responses in the central nervous
system (CNS) caused by gram-negative meningeal pathogens
(42). Inflammatory responses in the brain caused by the ad-
ministration of Escherichia coli LPS into the lateral ventricle
of rats reduce hepatic CYP1A1/2, CYP2B1/2, CYP2D1,
CYP2E1, and CYP3A1/2 enzyme activities and/or protein
levels (14, 27, 31, 40, 41, 45). The signaling mechanisms that
produce peripheral responses during CNS infection have been
proposed to include peripheral inflammatory cytokines, the
hypothalamic-adrenal-pituitary (HPA) axis, the sympathetic
nervous system, and reactive oxygen species (8, 15, 48).
Because of the complex nature of these signaling mechanisms,
it has been difficult to determine which pathways are most
important for the loss in hepatic drug metabolism in vivo. Mice
with disruptions of genes contributing to inflammatory signal-
ing pathways (TNF- receptor, IL-6, signal transducer and
activator of transcription-1, and nitric oxide synthase-2-null
mice) have been used as a tool to delineate the factors that are
important for decreasing hepatic drug metabolism during pe-
ripheral inflammatory responses (32, 43, 46, 50). The avail-
ability of mice with genetic alterations in immune signaling
pathways will allow a more precise mechanistic examination of
the biochemical links between CNS infection and inflammation
and drug metabolism and disposition in vivo.
Toll-like receptor-4 (TLR4) has been identified as the trans-
membrane receptor that specifically recognizes LPS and ini-
tiates intracellular signal transduction and an immune response
to that bacterial cell wall component (6, 36). LPS signaling
during conditions of systemic inflammation involves the bind-
ing of LPS to the serum protein LPS binding protein, followed
by association with CD14, a receptor found either in the
membrane or in soluble form. The complex is then thought to
translocate to TLR4 to initiate intracellular signal transduction
pathways, including NF-B activation and inflammatory cyto-
kine production (4, 6). A similar process occurs in the regions
of the brain (choroid plexus, leptomeninges, and circumven-
tricular organs) that coexpress the CD14 and TLR4 compo-
nents of the LPS signal transduction pathway (20, 30). Despite
the importance of TLR4 in LPS signaling, it has received
minimal attention with regard to regulation of drug metabolism
by inflammatory processes. C3H/HeJ mice contain a single
point mutation at amino acid 712 that renders TLR4 ineffective
and the mice unresponsive to stimulation by LPS (36, 37).
Thus the C3H/HeJ mouse strain represents a useful model to
examine whether changes in hepatic cytochrome P-450 expres-
sion during LPS exposure can be specifically attributed to
activation of TLR4 signaling pathways.
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The aim of this study was to examine the signaling mechanisms
responsible for the loss in hepatic cytochrome P-450 3A in a
model of gram-negative bacterial infection or inflammation of the
mouse brain. Our novel findings indicated that, in this experimen-
tal model, the flux of LPS from brain to blood and the activation
of a peripheral TLR4-mediated immune response lead to a reduc-
tion Cyp3a11 drug metabolism in the liver.
MATERIALS AND METHODS
Mice and production of CNS inflammation. FVB and C57BL/6
mouse strains were used initially in the study to develop methodology
and to characterize the effects of CNS infection or inflammation on
mouse cytochrome P-450 metabolism. Subsequently, the C3H/HeJ
and closely related C3H/HeouJ strains were used to specifically
address the role of TLR4 in mediating changes in hepatic cytochrome
P-450 expression and activity. Adult male mice (FVB strain) and
adrenalectomized FVB mice were obtained from Taconic Laborato-
ries (Germantown, NY). Male mice (6–8 wk old) containing either a
spontaneous mutation in TLR4 gene (C3H/HeJ) and age-matched
LPS-responsive (C3H/HeouJ) mice were obtained from The Jackson
Laboratory (Bar Harbor, ME). C57BL/6 mice were obtained from our
in-house breeding colony. The mice were housed in cages lined with
corncob bedding and had free access to water and Purina mouse chow.
Drinking water for adrenalectomized mice was supplemented with 5%
glucose. Mice were kept on a 12:12-h day-night cycle and were
allowed to acclimatize in the animal holding facilities for a period of
1 wk before experimentation. The Dalhousie University Committee
on Laboratory Animals approved all experimental procedures involv-
ing mice according to guidelines of the Canadian Council on Animal
Care.
On the day of the experiments, mice were anesthetized with
enflurane (3.0–4.0%) and were given an infusion of either endotoxin-
free saline (2.5 l) or gel-purified E. coli LPS (serotype 0127:B8; 2.5
g in 2.5 l) into the lateral cerebral ventricle [intracerebroventricular
(ICV)] using a Harvard Apparatus syringe pump. The solutions were
injected at a rate of 2.5 l/min. The coordinates for the sterotaxic
injections were 2.5 mm dorsal/ventral, 1.5 mm lateral, and 0.2
mm anterior/posterior from the bregma (11).
For the intraperitoneal experiments, mice were injected intraperi-
toneally with either a low (2.5 g) or high (125 g) dose of purified
E. coli LPS suspended in 100 l of 0.9% endotoxin-free saline.
Control mice were injected with 100 l of the saline vehicle.
Phenol-extracted LPS, but not the gel-purified LPS, contains mi-
cromolar levels of biologically active contaminants, including gluta-
mate and adenosine (16), which could precipitate nonspecific re-
sponses in our model. For those reasons, chromatographically purified
LPS is the preferred preparation for in vivo studies of this nature. To
assess blood-brain barrier permeability changes, a tracer amount (4
nmol) of D-[1-14C]mannitol was administered peripherally to control
mice and to mice 0, 1, 4, and 24 h after 2.5 g LPS was administered
into the lateral ventricle. Brain levels of total radioactivity were
measured by scintillation counting 1 h after the [14C]mannitol injec-
tion. For the TNF- experiment, 50 ng of recombinant mouse TNF-
(R&D systems) or vehicle containing sterile filtered PBS and 0.1% BSA
were administered into the lateral ventricle in a total volume of 2.5 l.
Tissue and microsome preparation. Mice were killed 4 or 24 h after
the ICV administration of either LPS or saline, at which point liver
and brain samples were obtained. The whole brain was homogenized
in 1.5 ml of PBS (pH 7.4) and spun at 13,000 rpm for 10 min. Brain
supernatants were stored at 80°C until utilized for cytokine mea-
surements. Samples (100 mg) were obtained from the liver and frozen
in liquid nitrogen for total RNA isolations. The remaining liver was
removed and used to prepare microsomes according to previously
published methods (10). We homogenized liver tissue in ice-cold
1.15% KCl for 15–20 s using a Polytron homogenizer. The homog-
enates were centrifuged at 10,000 g for 10 min at 4°C, and the
supernatants were recentrifuged at 110,000 g for 40 min. The resulting
microsomal pellets were resuspended in 0.8 ml of glycerol buffer (pH
7.5) that contained 50 mM KH2PO4, 20% glycerol, and 0.40% KCl.
Samples were stored at 80°C until enzymatic assays were per-
formed. Microsomal protein content was determined by the method of
Lowry et al. (23) using BSA as a standard.
Cyp3a11 enzyme assays. The formation of -hydroxytriazolam
from triazolam was used as a specific indicator for mouse Cyp3a11
activity (34). Incubation mixtures (performed in duplicate) contained
500 g of total microsomal protein, 20 M triazolam, and 1 mM
NADPH in 100 mM PBS (pH 7.4). The reaction mixtures (1 ml final
volume) were incubated in a 37°C water bath with a shaker set at 100
oscillations/min. After 15 min, the reactions were stopped by the
addition of 5 ml of dichloromethane; 2,000 ng of phenacetin were
added to each sample as an internal standard. The samples were then
centrifuged at 2,700 rpm for a period of 10 min, and the lower organic
phase containing the metabolites and internal standard was transferred
into a clean glass tube and evaporated to dryness using a nitrogen
evaporator followed by reconstitution in 200 l of HPLC mobile
phase. The HPLC mobile phase consisted of acetonitrile [20% (vol/
vol)] and methanol [35% (vol/vol)] in 0.01 M potassium phosphate
buffer (45% vol/vol) buffered to pH 7.4 with NaOH. Reconstituted
samples (50 l) were separated on a reverse-phase C-8 (25 cm  4.5
mm inner diameter) analytical column (Beckman Coulter, Fullerton,
CA) attached to a Waters 2690 separation module. The mobile phase
flow rate for separations was set at 1.0 ml/min. The approximate
retention times were 5.0 min for -hydroxytriazolam, 8.0 min for
phenacetin, and 12.0 min for triazolam; these were detected by UV
absorption at 220 nm (Waters 2487 Dual  absorption unit).
RNA isolation and Northern analyses. Total liver RNA was iso-
lated using TRIzol reagent (Invitrogen, Carlsbad, CA) according to
the manufacturer’s instructions. Quality of the RNA was determined
spectrally by measuring the 260-to-280-nm absorbance ratio and was
typically between 1.8 and 2.0. For Northern blot analyses, 10 g of
total RNA were resolved on a 1.1% agarose-formaldehyde denaturing
gel. RNA was transferred overnight to a nylon membrane (Immobilon
NY; Millipore, Bedford, MA) and was fixed to the membrane by UV
cross-linking and heating for 1 h at 65°C. [32P]CTP probes for mouse
Cyp3a11 and Gapdh mRNA were generated from the corresponding
cDNAs using the RmT Random Primer labeling kit according to
manufacturer’s instructions (Stratagene). Blots were prehybridized for
1 h at 65°C in 10 ml of Sigma Perfecthyb Plus (Sigma, St. Louis, MO)
followed by overnight hybridization with [32P]CTP probes. Blots
were exposed to storage phosphor screen (Amersham Biosciences,
Piscataway, NJ) for 16–24 h and scanned with a phosphor imager
(Amersham Biosciences). Quantification was performed using Image-
Quant 5.2 software (Amersham Biosciences).
Quantitative real-time PCR. Total RNA (5 g) was reverse tran-
scribed using Stratascript reverse transcriptase (Stratagene, Cedar
Creek, TX) with 12.5 ng/l random hexamers pd(N)6 and 1.0 mM
dNTPs according to the supplier’s instructions. We amplified cDNA
product (1 l) by quantitative PCR using 125 nM gene-specific
primers in a total volume of 20 l with brilliant SYBR green QPCR
Master Mix using the Stratagene MX3000p thermocycler. For TNF-,
a 61-bp product was generated with the forward 5	-CCC TCA CAC
TCA GAT CAT CTT CT-3	 and reverse 5	-GCT ACG ACG TGG
GCT ACA G-3	 primers (GenBank accession no. NM_013693). For
GAPDH, a 245-bp amplicon was generated with the forward 5	-AAG
GTC GGT GTG AAC GGA TTT GG-3	 and reverse 5	-TTG ATG
TTA GTG GGG TCT CGC TCC-3	 primers (GenBank accession no.
NM_008084). The amplification protocol consisted of a 10-min hot
start at 94°C, followed by 40 cycles of denaturation at 94°C for 15 s,
annealing at 60°C for 18 s, and elongation at 72°C for 30 s. Melting
curves followed by separation of PCR products on a 2.5% agarose gel
were used to ensure the formation of a single product at the appro-
priate size. The threshold cycle values for TNF- and control gene
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Gapdh were obtained with a threshold of 3 SD above background.
Relative TNF- expression normalized to Gapdh was calculated using
the 

CT (where CT is threshold cycle) method (see Ref. 22).
Cytokine measurements. We measured the levels of TNF- and
IL-1 in brain homogenates and serum 2 or 4 h after LPS adminis-
tration ICV using a murine sandwich ELISA prepared as previously
described (26). The results are expressed as nanograms of cytokine
per gram of brain wet weight or nanograms of cytokine per milliliter
of serum.
Serum LPS measurements. LPS (2.5 g) was administered by the
ICV or intraperitoneal route to endotoxin-responsive C3H/HeouJ
mice. Mice were killed 15 min, 30 min, 2 h, or 24 h later, and trunk
blood was collected. All groups were compared with noninjected
control mice. We measured serum LPS levels using the kinetic
chromogenic Limulus amebocyte lysate assay as per the manufac-
turer’s instructions (Associates of Cape Cod, Cape Cod, MA). The
assay was linear from 0.395 pg/ml to 100 ng/ml LPS. We calculated
the area under the curve (AUC0.25–2 h) from the mean serum LPS
concentrations using the trapezoidal method.
Data analyses. Data are expressed as means  SE of three or four
separate animals. An unpaired t-test was used to compare means
between two groups. ANOVA was used for multiple-comparison
procedures. A Tukey’s test was used for post hoc analysis of the
significant ANOVA. A difference in mean values with a value of P 
0.05 was considered to be significant.
Chemicals. Purified E. coli LPS (serotype 0127:B8), phenacetin,
-hydroxytriazolam, ethoxyresorufin, resorufin, NADPH, and dichlo-
romethane were obtained from Sigma. [32P]dCTP was obtained from
Perkin-Elmer (Boston, MA). Triazolam was obtained from Roche
Pharmaceuticals. All other reagents were of the finest grade available
and were purchased from commercial suppliers.
RESULTS
Administration of LPS into the lateral ventricle reduces
hepatic Cyp3a11 expression and activity. The initial experi-
ments carried out in the two mouse strains (FVB and C57BL/6)
were required to develop a mouse model of CNS infection and
inflammation and to determine whether this model exhibited
reductions in Cyp3a11 expression and activity. The dose of
LPS was based on previous studies that demonstrated that 0.1
g/kg LPS administered ICV was required for significant
downregulation of hepatic cytochrome P-450 enzymes in rats
(14, 31, 41). The expression of Cyp3a11 and Gapdh mRNA
was measured in the liver by Northern blot analyses 4 and 24 h
after the administration of E. coli LPS into the left lateral
cerebral ventricle (Fig. 1A). Cyp3a11 mRNA was unchanged at
4 h and was decreased by 60% 24 h after LPS treatment
compared with the respective saline controls (Fig. 1, B and D).
Liver Gapdh expression was not altered by LPS treatment.
Consistent with mRNA expression, the rate of -hydroxylation
of triazolam (Cyp3a11 activity) was unchanged at 4 h but was
decreased by 60% at 24 h by LPS treatment compared with the
respective saline control (Fig. 1, C and E). LPS (2.5 g)
administered ICV to C57BL/6 mice produced a similar reduc-
tion in Cyp3a11 mRNA (80%) and -hydroxylation of triazo-
lam (60%) and indicated that the effect of LPS was not
restricted to the FVB strain of mice (Fig. 2).
Administration of LPS into the lateral cerebral ventricle
produces CNS inflammation. Two hours after LPS was admin-
istered into the lateral ventricle of FVB mice, TNF- and Il-1
levels were significantly increased (2-fold) compared with the
saline controls (Fig. 3, A and B). The increased level of TNF-
and Il-1 are consistent with the production of CNS inflam-
mation in response to LPS. A parallel increase (2-fold) in
TNF- and IL-1 in serum indicated a systemic response to
ICV administered LPS (Fig. 3, C and D).
HPA axis does not mediate hepatic Cyp3a11 downregula-
tion following ICV administration of LPS. The release of
inflammatory cytokines after LPS injection into the brain is
known to activate the HPA axis and increase circulating
corticosteroids, which can affect the acute phase response and
gene transcription in the liver (2, 9, 48). Thus it was important
to determine the relevance of the HPA axis in contributing to
the downregulation of Cyp3a11 mRNA and enzyme activity in
our model (Fig. 4). Adrenalectomized and control FVB mice
were left untreated or were injected with 2.5 g or LPS or
saline ICV. LPS reduced Cyp3a11 expression and activity to
the same degree (70%) in both control and adrenalectomized
Fig. 1. Hepatic Cyp3a11 mRNA and activity were downregulated 24 h after
intracerebroventricular (ICV) administration of LPS (2.5 g) to male FVB
mice. A: representative Northern blots of Cyp3a11 and Gapdh at 4 and 24 h
after ICV administration of LPS or saline. Band intensities were determined by
densitometry, and hepatic Cyp3a11 (B and D) mRNA was normalized to
Gapdh mRNA. Cyp3a11 activity was measured 4 h (C) and 24 h (E) after LPS
or saline administration by monitoring the formation of -hydroxytriazolam
(-OH-triazolam) from triazolam in liver microsomal fractions. Each bar
represents the mean SE of 4 mice. *Cyp3a11 mRNA and activity were lower
compared with the respective saline-treated mice (P  0.05, unpaired t-test).
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mice (Fig. 4, A–C). In control mice and adrenalectomized mice,
saline administration had no effect on hepatic Cyp3a11 mRNA or
triazolam metabolism compared with the respective untreated
animals. Similarly, basal Cyp3a11 expression and triazolam hy-
droxylation in adrenalectomized mice was not significantly dif-
ferent from controls. ICV LPS in control mice significantly
increased serum corticosterone compared with saline-treated or
untreated control mice, indicating activation of the HPA axis (Fig.
4D). Adrenalectomy completely prevented the elevation in serum
corticosterone after ICV administration of LPS.
TLR4 signaling regulates hepatic Cyp3a11 expression.
TLR4-expressing (C3H/HeouJ) and TLR4 mutant (C3H/HeJ)
mice were utilized to determine whether the downregulation of
hepatic Cyp3a11 by LPS was mediated through stimulation of
the TLR4. Twenty-four hours after LPS (2.5 g) administra-
tion to C3H/HeouJ mice, Cyp3a11 mRNA was decreased by
70% compared with the saline control (Fig. 5, A and B). In
sharp contrast, no loss in Cyp3a11 mRNA was evoked 24 h
after LPS was administered directly into the lateral cerebral
ventricle of TLR4 mutant (C3H/HeJ) mice. Liver Gapdh ex-
pression was similar in both mouse strains and was not altered
by LPS treatment. Correspondingly, triazolam metabolism to
-hydroxytriazolam was reduced by 60% in the C3H/HeouJ
(wild-type) mice but was unchanged in the C3H/HeJ (TLR4
mutant) mice compared with the respective saline controls
(Fig. 5C). Basal Cyp3a11 mRNA and triazolam hydroxylation
were 40% lower in saline-treated C3H/HeJ vs. C3H/HeouJ
mice. After 4 h, LPS increased brain TNF- protein in the
C3H/HeouJ mice but not in the C3H/HeJ mice compared with
the respective saline controls (Fig. 5D). Liver TNF- mRNA
expression was increased 60-fold in the C3H/HeouJ mice but
only 5-fold in the C3H/HeJ mice 4 h after LPS treatment
compared with the respective saline controls (Fig. 5E). These
results demonstrate an inhibition of the brain and liver inflam-
matory responses to LPS in the TLR4-mutant C3H/HeJ mice
and indicate that the reduction in hepatic Cyp3a11 expression
and activity are linked to stimulation of TLR4 by LPS. Re-
combinant TNF- (50 ng) administered ICV to the C3H/HeouJ
and C3H/HeJ mice did not produce a loss in Cyp3a11 expres-
sion in either mouse strain 24 h after they were dosed (Fig. 5F).
The dose of TNF- was chosen to approximate the TNF-
level detected in the brain 2–4 h after the LPS dose.
LPS is rapidly transferred from the CNS to the periphery
after administration into the lateral cerebral ventricle. During
CNS infection, the leakage of endotoxin into the periphery
could play a role in reducing hepatic cytochrome P-450 me-
tabolism; however, the systemic distribution of LPS after its
administration ICV has not been previously characterized. LPS
(2.5 g) administered by the ICV route was detected in the
serum (1,000–10,000 pg/ml range) between 15 min and 2 h
after mice were dosed. LPS was not detectable in the serum
24 h after ICV administration or in untreated control mice (Fig.
6A). When 2.5 g of LPS were administered via the intraperi-
toneal route, the levels of endotoxin detected were very similar
to those obtained after administration of LPS by the ICV route
(Fig. 6B). The intraperitoneal administration of 2.5 g LPS
also produced a 60% reduction in hepatic Cyp3a11 mRNA and
triazolam metabolism (Fig. 6, C–E). The AUC0.25–2 h results
calculated for the serum LPS data were 11,817 and 8,847
pg ml1 h1 after ICV and intraperitoneal injection of LPS,
respectively. This result directly supports the idea that a pe-
ripheral inflammatory response produced by LPS reaching the
circulation after ICV injection is sufficient to produce reduc-
tions in hepatic cytochrome P-450 metabolism. The uptake of
peripherally administered [14C]mannitol was used as a marker
of changes in blood-brain permeability induced by ICV admin-
istration of LPS (Fig. 6F). Increased blood-brain permeability
was suggested by the significant increase in total brain
[14C]mannitol 5 and 24 h after LPS administration compared
with control mice.
Fig. 3. Brain and serum inflammatory cytokines were elevated after ICV
administration of LPS. Male FVB mice were injected with 2.5 g of LPS or
2.5 l of saline into the lateral cerebral ventricle. Levels of TNF- and IL-1
proteins in brain (A and B) and serum (C and D) were measured 2 h after ICV
administration of LPS or saline. Each bar represents the mean  SE of 4 mice.
*Mean cytokine levels were higher compared with the respective saline-treated
control (P  0.05, unpaired t-test).
Fig. 2. Hepatic Cyp3a11 mRNA and activity were downregulated 24 h after ICV
administration of LPS (2.5 g) to male C57BL/6 mice. A: hepatic Cyp3a11
mRNA expression normalized to Gapdh expression as determined by Northern
blot analysis. Band intensities were determined by densitometry. Cyp3a11 activity
was measured by monitoring the formation of -OH-triazolam from triazolam in
liver microsomal fractions (B). Each bar represents the mean  SE of 4 mice.
*P  0.05 compared with the respective saline-treated mice (unpaired t-test).
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Systemic administration of LPS mediates a reduction in
hepatic Cyp3a11 expression and activity through TLR4 signal-
ing. The importance of TLR4 in mediating hepatic Cyp3a11
downregulation after the administration of LPS by the intra-
Fig. 5. Toll-like receptor-4 (TLR4) mutant mice (C3H/HeJ) are resistant to
downregulation of Cyp3a11 mRNA and activity after ICV administration of LPS.
TLR4 mutant (C3H/HeJ) and wild-type (C3H/HeouJ) mice were injected with 2.5
g of LPS or 2.5 l of saline into the lateral cerebral ventricle. A: representative
Northern blots of Cyp3a11 and Gapdh. B: hepatic Cyp3a11/Gapdh mRNA
expression as determined by densitometry. C: Cyp3a11 enzyme activity (-OH-
triazolam formation) 24 h after treatment. D: TNF- protein was measured by
ELISA in brain homogenates 4 h after ICV injection of LPS as a marker of the
central nervous system (CNS) inflammatory response. E: TNF- mRNA was
measured in liver 4 h after ICV injection of LPS as a marker of an inflammatory
response in that organ. F: effect of ICV administration of 50 ng of TNF- on
hepatic Cyp3a11 expression. Each bar represents the mean  SE of 4 mice.
*Different in LPS-treated compared with respective saline-treated mice (P  0.05).
†Cyp3a11 mRNA and activity were lower in saline-treated C3H/HeJ mice compared
with saline-treated C3H/HeouJ mice, and ‡TNF- was lower compared with LPS-
treated C3H/HeouJ mice (P  0.05, ANOVA followed by Tukey’s post hoc test).
Fig. 4. Hypothalamic-adrenal-pituitary (HPA) axis does not contribute to
hepatic Cyp3a11 downregulation after ICV administration of LPS. Experiment
was performed 2 wk after adrenalectomy. Control (Con) mice and adrenalec-
tomized (ADX) mice were injected with 2.5 g of LPS or 2.5 l of saline into
the lateral cerebral ventricle. Analyses were performed 24 h after the ICV
injections. A: representative Northern blots for hepatic Cyp3a11 and Gapdh. B:
hepatic Cyp3a11/Gapdh expression as determined by densitometry. C: hepatic
Cyp3a11 activity (-OH-triazolam formation). D: serum corticosterone level.
For the corticosterone measurement, the LPS-ADX (adrenalectomy) bar rep-
resents the average of 2 mice. All other bars represent means  SE of 3 or 4
mice. *Different compared with the respective saline-treated control or the
untreated control (P  0.05, ANOVA followed by Tukey’s post hoc test).
Statistical comparison of serum corticosterone in the ADX mice was not
performed because of insufficient sample size (n  2) in the LPS-ADX group.
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peritoneal route was examined with TLR4-expressing and
TLR4 mutant mice. In C3H/HeouJ mice, a high dose (5 mg/kg)
of LPS produced a 90% reduction in Cyp3a11 mRNA and a
corresponding 60% loss of -hydroxytriazolam formation (Fig.
7). In contrast, TLR4 mutant (C3H/HeJ) mice were completely
resistant to the loss in Cyp3a11 mRNA and activity produced
by the high dose of LPS administered intraperitoneally. These
data identify that peripheral TLR4 stimulation is a requirement
for the downregulation of the major drug-metabolizing hepatic
cytochrome P-450 enzyme by systemic E. coli LPS.
DISCUSSION
In experimental models of CNS infection and/or inflamma-
tion, the central administration of LPS produces an inflamma-
tory response in the brain characterized by the activation of
microglia, astrocytes, and proinflammatory cytokine pathways;
the release of inflammatory cytokines (TNF-, IL-1, and
IL-6); and leukocyte infiltration (30, 35). The CNS inflamma-
tory response in our mouse model was confirmed by the
presence of elevated inflammatory cytokines (TNF- and IL-
1) in the brains of LPS-treated FVB or C3H/HeouJ mice. We
have observed a significant downregulation of expression and
metabolic activity of hepatic Cyp3a11 in FVB, C57BL/6, and
C3H/HeouJ mice but not in C3H/HeJ mice. A large reduction
in hepatic CYP3A metabolism produced by an inflammatory
response would have implications for drug toxicity because the
cytochrome P-450 subfamily metabolizes a large percentage of
Fig. 7. Regulation of hepatic Cyp3a11 metabolism by systemic LPS is medi-
ated via TLR4 signaling pathways. TLR4 mutant (C3H/HeJ) and wild-type
(C3H/HeouJ) mice were injected with 125 g (5 mg/kg) of LPS or saline into
the peritoneal cavity. A: hepatic Cyp3a11/Gapdh mRNA expression as mea-
sured by densitometry. B: Cyp3a11 enzyme activity 24 h after IP injection of
LPS. Each bar represents the mean  SE of 4 mice. *Cyp3a11 expression or
activity was lower compared with the saline-treated C3H/HeouJ mice (P 
0.05). †Cyp3a11 expression in the C3H/HeJ mice was different compared with
the respective saline-treated or LPS-treated C3H/HeouJ mice (P  0.05,
ANOVA followed by Tukey’s post hoc test).
Fig. 6. After ICV administration, LPS is transferred from the brain to the
periphery. Serum endotoxin levels were measured by the kinetic chromogenic
Limulus ameboctye lysate assay in noninjected mice or at various times after
2.5 g of LPS were administered ICV (A) or intraperitoneally (IP) (B) to
C3H/HeouJ mice. ND, not determined. C: Northern blots for hepatic Cyp3a11
and Gapdh mRNA. D: hepatic Cyp3a11/Gapdh mRNA expression determined
by densitometry. E: hepatic microsomal Cyp3a11 activity (-OH-triazolam
formation) 24 h after IP administration of 2.5 g of LPS or saline to
C3H/HeouJ mice. F: brain accumulation of peripherally administered
[14C]mannitol (4 nmol) was used as marker of blood-brain solute permeability
changes at various times after ICV injection of 2.5 g of LPS. Each bar
represents the mean  SE of 3 or 4 mice. D and E: *Cyp3a11 mRNA or
enzyme activity was lower compared with the saline-treated control (P  0.05,
unpaired t-test). F: *P  0.05 compared with control (ANOVA followed by
Tukey’s honestly significant difference test).
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clinically used drugs in humans (1). The present results were
not restricted to Cyp3a11 expression as similar losses in
hepatic Cyp1a1 expression were generated by the imposed
experimental conditions (Fig. 8). The extent (50–70%) of
hepatic cytochrome P-450 downregulation in the mouse was
similar to the loss in hepatic cytochromes P-450 that occurred
in our laboratory’s previously established rat model of CNS
infection/inflammation (14, 31, 41).
The existence of a pathway to activate a peripheral acute
phase response during infections of the CNS was supported by
the previous observations that inflammatory cytokine levels in
the periphery were elevated and the hepatic acute phase re-
sponse was stimulated (8, 15, 48, 51). This undetermined
signaling pathway has been proposed to regulate drug metab-
olism in the liver during CNS infections or inflammation (41,
45). The HPA axis is activated by cytokines during the acute
phase response and may have a suppressive role against the
reduction of ethoxyresorufin O-deethylase (Cyp1a), pen-
toxyresorufin O-depentylase (Cyp2b), imipramine N-demeth-
ylase (Cyp2d), and erythromycin N-demethylase (Cyp3a) me-
tabolism after ICV injection of LPS to rats (9, 45, 48). In the
present study, adrenalectomy prevented the elevation of
plasma corticosterone but did not protect or enhance the
LPS-evoked depression in hepatic Cyp3a11 expression and
activity after LPS administration. This confirms that the HPA
axis plays no role in hepatic Cyp3a11 downregulation in the
mouse model of CNS infection or inflammation. Others have
examined the stimulation of the sympathetic nervous system or
transduction of TNF-, IL-1, and IFN- from the brain to the
periphery, but neither of these pathways could explain the link
between CNS infection/inflammation and the loss in hepatic
cytochrome P-450 enzyme activity in rats (31, 39, 45). Con-
sistent with the findings of Nicholson et al. (31), in the present
study, centrally administered TNF- did not reduce Cyp3a11
expression in C3H/HeouJ or C3H/HeJ mice, suggesting that
CNS-derived TNF- is not the major factor involved in down-
regulation of hepatic Cyp3a11 after the ICV injection of LPS.
IL-6 could also contribute to Cyp3a11 downregulation. How-
ever, LPS decreased hepatic Cyp3a11 expression by 80% in
both IL-6-expressing and IL-6-null mice and suggested against
a major role for that cytokine for the downregulation of
Cyp3a11 expression by LPS (46).
LPS has been identified as a specific ligand of TLR4 (6, 36).
Signaling through the LPS receptor (TLR4) is an additional
pathway that could initiate the reduction in hepatic drug me-
tabolism in the model of CNS inflammation. We observed that
the TLR4 mutants (C3H/HeJ mice) were totally resistant to the
LPS-mediated loss in hepatic Cyp3a11 expression and activity
that was observed in mice that express functional TLR4. Basal
levels of Cyp3a11 mRNA expression and triazolam hydroxy-
lation were reduced in the C3H/HeJ mice. On the basis of those
data, C3H/HeJ mice behaved phenotypically as slow metabo-
lizers of triazolam, whereas C3H/HeouJ mice were fast me-
tabolizers of the drug. The LPS effect in C3H/HeouJ mice was
functionally significant because it was able to change the
metabolic phenotype of the C3H/HeouJ mice from that of a fast
metabolizer to that of a slow metabolizer of triazolam. Several
of our findings also support that C3H/HeJ mice are resistant to
LPS-mediated reductions in Cyp3a11 expression and activity
because of inhibition of signal transduction through the TLR4
and not because of reduced basal expression of that cyto-
chrome P-450 gene. First, it was clear from the peripheral
inflammation study that LPS could reduce Cyp3a11 mRNA
and triazolam hydroxylation in C3H/HeouJ mice below basal
levels in the C3H/HeJ mice. Second, basal Cyp1a1 expression
was similar in C3H/HeouJ and C3H/HeJ (Fig. 8) mice but was
only depressed by LPS in the C3H/HeouJ mice. Finally,
hyporesponsiveness to LPS in the TLR4-mutant mice was
confirmed by the lack of a TNF- response in the brain and
liver.
The lack of the TNF- response in C3H/HeJ mice after the
ICV administration of LPS indicated the absence of a CNS
inflammatory response. However, we could not conclude that
Fig. 8. Regulation of hepatic Cyp1a1 mRNA expression by E. coli LPS. In
A–C, mice received ICV injection of LPS (2.5 g) or saline (2.5 l). Hepatic
Cyp1a1 levels were measured 24 h after treatment. ICV treatment with LPS
decreased hepatic Cyp1a1 mRNA in male FVB mice (A) and in TLR4-
expressing (C3H/HeouJ) mice but in not TLR4 mutant (C3H/HeJ) mice (B)
and in control and adrenalectomized FVB mice (C) compared with relative
saline controls and/or naive mice. D: hepatic Cyp1a1 mRNA was decreased
(45%) 24 h after IP administration of LPS (2.5 g) to C3H/HeouJ mice
compared with that in saline-injected control mice. E: hepatic Cyp1a1 mRNA
was decreased (85%) 24 h after IP administration of 125 g of LPS to
TLR4-expressing (C3H/HeouJ) but not TLR4 mutant (C3H/HeJ) mice com-
pared with that in the respective saline controls. Each bar represents the
mean  SE of 3 or 4 samples. An unpaired t-test was used for statistical
comparison in A and D. ANOVA was used for statistical comparison in B, C,
and E. *P  0.05 compared with the respective saline-treated mice. †P  0.05
compared with the respective naive mice (C). ‡P  0.05 compared with
LPS-treated C3H/HeouJ mice (B and E). Mean Cyp1a1 mRNA level in
LPS-treated adrenalectomized mice approached statistical significance com-
pared with the saline control (P  0.06).
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blockade of the CNS inflammatory response was the only
factor that protected the TLR4 mutant mice from the loss in
hepatic Cyp3a11 because TLR4 are also present on peripheral
macrophages and hepatocytes and could still elicit an immune
response to E. coli LPS (4, 21). This idea of a peripheral
inflammatory response is supported by the observation that
liver TNF- mRNA and serum levels of TNF- and IL-1
were elevated by ICV administered LPS. If LPS was secreted
into the blood from the cerebral spinal fluid, then a resulting
peripheral inflammatory response could explain the decrease in
hepatic Cyp3a11 metabolism.
Several studies have suggested that LPS was restricted to the
CNS when it was injected into the lateral ventricle of the brain
(41, 45). In contrast, the present observations provide convinc-
ing evidence that LPS is not restricted to the CNS after central
administration and is transferred to the blood in significant
quantities. Similar quantities of LPS were detected in serum,
and a similar loss in hepatic Cyp3a11 expression and activity
was observed after the intraperitoneal administration of LPS
(2.5 g). The systemic bioavailability, as approximated by
AUC, was similar after both routes of administration. These
results indicated that, after ICV administration, the amount of
LPS reaching the systemic circulation is large enough to alter
hepatic cytochrome P-450 solely by actions in peripheral
tissues. Thus a transfer of LPS from the CNS may have lead to
the previous observation of reduced hepatic cytochrome P-450
after ICV administration of LPS to rats (41, 45).
E. coli LPS (0127:B8, 200 g) injected ICV to rats increased
blood-brain barrier permeability between 4 and 16 h after the
injection (18). Changes in blood-brain barrier permeability
could result in LPS leakage into the peripheral circulation.
However, our experimental results suggested that peak LPS
transfer (between 1 and 2 h) from the ventricles occurred on a
time scale that preceded the opening of the blood-brain barrier.
The majority of cerebral spinal fluid is resorbed by bulk flow
into the systemic circulation via transfer from the subarchnoid
villi into the superior sagittal venous sinus (7). The bulk flow
mechanism begins to return other blood-brain barrier-imper-
meable substances (albumin and leptin) to the systemic circu-
lation within minutes of their injection by the ICV route (7,
24). Thus the bulk flow reabsorption of cerebral spinal fluid is
likely the more important mechanism for LPS transfer to the
peripheral circulation as opposed to passage across the blood-
brain barrier.
The decrease in hepatic Cyp3a11 expression and activity in
response to circulating levels of LPS also appears to involve
TLR4, as the intraperitoneal injection of LPS had no effect in
TLR4-mutant mice. Others have shown that C3H/HeJ mice
were resistant to LPS downregulation of hepatic ethoxycou-
marin dealkylase (Cyp2a) and ethoxyresorufin dealkylase
(Cyp1a/2) enzyme activities 24 h after LPS was administered
intraperitoneally, but this work was conducted before the
identification of TLR4 as a critical component of the LPS
signal transduction pathway (13, 44). Also, in a model of
indomethacin-induced intestinal injury, TLR4 activation by
LPS released from intestinal flora may contribute to downregu-
lation of hepatic Cyp3a11, Cyp1a1/2, and Cyp2d9 enzyme
activities (25). Together, these results directly support the idea
that peripheral TLR4 are involved in the regulation of hepatic
cytochrome P-450 enzymes by peripherally administered LPS.
TLR4-mediated signaling occurs through two intracellular
pathways (47). The MyD88-dependent pathway results in the
direct induction of inflammatory cytokines (e.g., TNF, IL-1,
and IL-6). The MyD88-independent pathway activates NF-B
with delayed kinetics as well as the interferon response fac-
tor-3, which upregulates the expression of interferon-inducible
genes. Although not determined in the present study, experi-
ments in MyD88-deficient and interferon response factor-3-
deficient mice should reveal which of these two pathways is
most important for Cyp3a11 downregulation by LPS.
Our findings have led to a putative model of how CNS
infection could lead to the loss of cytochrome P-450 expres-
sion and activity in the liver, as shown in Fig. 9. LPS injected
within the lateral ventricle produces TLR4-dependent CNS
inflammation. The localized inflammation is likely important
for the loss in cytochrome P-450 that occurs in the brain (41)
but is not the major factor that depresses cytochrome P-450
Fig. 9. Downregulating hepatic cytochrome P-450 metabolism in a model of
gram-negative bacterial infection of the CNS. LPS injected within the lateral
ventricle produces TLR4-dependent CNS inflammation, which may be impor-
tant for decreased cytochrome P-450 activity in the brain but is not likely the
major factor that reduces hepatic cytochrome P-450 metabolism. We demon-
strate an alternative mechanism in which centrally administered LPS is rapidly
transferred from the cerebral spinal fluid (CSF) to the blood. Peripheral LPS
activates TLR4-dependent inflammatory pathways in peripheral immune cells
(e.g., macrophages), leading to an elevation in circulating inflammatory cyto-
kines (e.g., TNF-, IL-1, and IL-6). It is well known that those inflammatory
cytokines activate signal transduction pathways within the hepatocyte and the
expression/activation hepatic transcription factors (e.g., NF-B), which inhibit
expression of cytochrome P-450. Additionally, direct LPS stimulation of
TLR4 signaling pathways in the hepatocyte represents a potential pathway that
could trigger intracellular events that lead to Cyp3a11 downregulation. TF,
transcription factor; Cyt R, cytokine receptor; , activation; , inhibition or
downregulation.
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metabolism in the liver. We propose that centrally adminis-
tered LPS is rapidly transferred from the cerebral spinal fluid to
the blood. Through a TLR4-dependent mechanism, circulating
LPS then reduces hepatic Cyp3a11 mRNA expression and
enzyme activity. The loss of hepatic cytochrome P-450 pro-
duced by systemic LPS could occur indirectly through the
action of circulating cytokines such as TNF-, IL-1, and IL-6
that are released from a peripheral source (e.g., macrophages or
Kupffer cells) (12, 13, 28, 31, 39, 44). Those cytokines activate
nuclear transcription factors within the hepatocyte, which reg-
ulate cytochrome P-450 expression in the liver (2, 3, 17, 19,
29, 33, 38). Despite the direct link between cytokines and
cytochrome P-450 expression, large doses of LPS (1–5 mg/kg)
were able to mediate hepatic Cyp3a11 downregulation in vivo
in mice with targeted disruptions in IL-6 and the TNF-
receptor (46, 50). This could be explained by the observations
that LPS stimulates NF-B signaling in isolated hepatocytes
through TLR4 present on those cells (21, 49). Thus the direct
action of LPS on the hepatocyte represents a potential mech-
anism for Cyp3a11 downregulation in the liver.
In summary, in the presence of a CNS infection, the transfer
of endotoxin from the brain to the periphery could stimulate a
peripheral immune response that produces a loss in cytochrome
P-450-mediated drug metabolism in the liver. We have also
identified that stimulation of TLR4 is responsible for linking
the immune response to E. coli endotoxin with a major drug
metabolizing cytochrome P-450 in the mouse liver. The reduc-
tion in cytochrome P-450 enzymes during inflammatory re-
sponses or infections of the CNS may reduce the metabolism
and elimination of several clinically used drugs and increase
the potential for adverse drug interactions.
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